Stock Spotlight: ResMed Inc. (ASX:RMD)
This week's Stock Spotlight is ASX-listed ResMed Inc.
About ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Key Stats
Key Stats
Source: EODHD. Data as of 04/02/26.
Price Performance
Growth Potential
- Global leader in a significantly under-penetrated sleep apnea market. High barriers to entry in establishing global distribution channels.
- Strong R&D program ensuring RMD remains ahead of competitors.
- New product launches (momentum in new mask releases) & buildout of portfolio via bolt-on acquisitions is seeing RMD become the one-stop shop for sleep apnea.
- Increasing popularity of GLP-1s is increasing awareness with studies indicating patients with an OSA diagnosis and prescribed a GLP-1 drug are 11% more likely to initiate PAP therapy.
- Strong balance sheet and attractive free cash flow profile provides management significant strategic flexibility.
- Solid FY26 guidance with further upside to gross margin.
- Capital management – active share buyback (shares to be repurchased expected at >$600m for FY26)
Key Risks
- Disruptive technology leads to better patient compliance or introduction of alternative therapies (GLP-1 weight loss drugs).
- Product recall leading to reputational damage.
- Competitive threats lead to market share loss – e.g. pharmaceutical threats to the CPAP market.
- Disappointing growth (company and industry specific).
- Adverse currency movements (AUD, EUR, USD).
- Adverse changes in regulatory & government funding
Subscribe to our newsletter
Disclaimer: This article does not constitute financial advice nor a recommendation to invest in the securities listed. The information presented is intended to be of a factual nature only. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing.
